NCT05525845

Brief Summary

The purpose of this study is to investigate how gut hormones and brain areas respond differently to gastric distention, tasteless calories, or palatable food and how this alters appetite.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable healthy

Timeline
27mo left

Started Sep 2022

Longer than P75 for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Sep 2022Aug 2028

First Submitted

Initial submission to the registry

August 16, 2022

Completed
17 days until next milestone

First Posted

Study publicly available on registry

September 2, 2022

Completed
6 days until next milestone

Study Start

First participant enrolled

September 8, 2022

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2028

Last Updated

September 18, 2025

Status Verified

September 1, 2025

Enrollment Period

5.9 years

First QC Date

August 16, 2022

Last Update Submit

September 13, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Difference in Cerebral Blood Flow related to hypothalamus

    The mean difference in cerebral blood flow (CBF) at fullness (satiation) and return to hunger (satiety) to the hypothalamic area.

    1 month

Secondary Outcomes (9)

  • Cerebral Bloodflow related in multiple brain areas

    1 month

  • Cerebral Blood Flow between three stimuli

    1 month

  • Hormone level

    1 month

  • comparison of calories

    1 month

  • calorie corellation to hormones

    1 month

  • +4 more secondary outcomes

Study Arms (1)

Food-Print Main Arm

OTHER

Functional Magnetic Resonance Imaging (pCASL-MRI) after Caloric and Volumetric stimulus in lean patients will be performed on all patients in the study

Other: Functional Magnetic Resonance Imaging (pCASL-MRI)Other: Intragastric BalloonOther: Elemental MealOther: Hedonic Meal

Interventions

MRI's will be performed at multiple points on each visit day.

Food-Print Main Arm

Intragastric Balloon will be placed during Visit 2 study day and inflated to maximum tolerated volume. Patient will then be scanned in the MRI.

Also known as: IGB
Food-Print Main Arm

Patient will ingest the tasteless elemental meal until their maximum level of fullness. Once full, the patient will be scanned in the MRI.

Food-Print Main Arm

Patient will ingest meal of their choice from a local food delivery service and eat until they reach their maximum level of fullness. Once full, the patient will be scanned in the MRI

Food-Print Main Arm

Eligibility Criteria

Age21 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI 18-25 kg/m\^2.
  • Weight stable for 3 months prior to study entry.
  • For females: study days will be scheduled during the follicular phase of their menstrual cycle (i.e., the first 13 days (about 2 weeks) of the cycle).
  • Able to provide written informed consent prior to any study procedures and be willing and able to follow study procedures..
  • Ability to perform light to moderate physical activity.

You may not qualify if:

  • Any contraindication for MRI scanning.
  • Any history of childhood (\> 95th percentile) or adult obesity (BMI \>30 kg/m\^2).
  • Claustrophobia.
  • High intensity training or physical activity.
  • Any contraindication for intragastric balloon insertion.
  • Any allergies to the study meals.
  • Any history of eating disorder.
  • Any substance abuse disorder (including alcohol and tobacco).
  • Any history of psychiatric disorders.
  • Any cardiovascular, endocrine, pulmonary, neurological, or gastrointestinal comorbidities.
  • Pregnancy or nursing.
  • Any history of bariatric surgery or endoscopic bariatric procedure.
  • Use of any medication or supplement that alters appetite.
  • Patient has a known history of any condition or factor judged by the investigator to prevent participation in the study or which might hinder study adherence.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States

RECRUITING

Related Links

MeSH Terms

Interventions

immunoglobulin B

Study Officials

  • Andres Acosta, MD, PhD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 16, 2022

First Posted

September 2, 2022

Study Start

September 8, 2022

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

August 1, 2028

Last Updated

September 18, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations